Cervical Fluid for Human Papilloma Virus and p16 Testing
Investigator: Megan Huchko, MD
Sponsor: Universitat Heidelberg
Cervical cancer screening among HIV-infected women is an important public health challenge in low-resource settings. High risk HPV (HR-HPV) testing, although appealing in ease of collection and reproducibility, has limited specificity for cervical intraepithelial neoplasia (CIN) due to high co-infection rates in this population. ELISA-based quantification of p16INK4a from exfoliated cervical cells has the potential for higher specificity, and its performance should be explored alone and in combination with HR-HPV testing in this population.